Janssen submits application to U.S. FDA seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
Expanded Access Program Established for Patients in the U.S. Who May Benefit from Investigational Therapy While Application is Under Review RARITAN, N.J.–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the